Mengyuan Li

8.5k citations
219 papers · 5.5k indexed · 2 hit papers · h-index 32
Topics
Cancer Immunotherapy and Biomarkers (18 papers)Ferroptosis and cancer prognosis (15 papers)Inflammasome and immune disorders (13 papers)
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Mengyuan Li

205 papers receiving 5.5k citations

Hit Papers

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a...2020202620222024202020232505007501000

Peers

Mengyuan Li
Comparison fields: 5 of 166
  • Molecular Biology 1.9k
  • Infectious Diseases 1.2k
  • Oncology 1.1k
  • Immunology 953
  • Cancer Research 799
Replace Xiang Chen with:
Xiang Chen China
Guanmin Jiang China
Ze‐Guang Han China
Shemin Lu China
Hongcui Cao China
Hui Li China
Fangfang Zhou China
Juan Chen China
Luca Falzone Italy
Mengyuan Li relative to Xiang Chen China Xiang Chen's profile →
Citations per field
00.5×1.5×
Xiang Chen · 1×
Citations per year

Countries citing papers authored by Mengyuan Li

Since Specialization
Citations

This map shows the geographic impact of Mengyuan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengyuan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengyuan Li more than expected).

Fields of papers citing papers by Mengyuan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengyuan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengyuan Li. The network helps show where Mengyuan Li may publish in the future.

Co-authorship network of co-authors of Mengyuan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Mengyuan Li. A scholar is included among the top collaborators of Mengyuan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengyuan Li. Mengyuan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 14
3 1
4 3
5 2
6 2
7 5
8 27
9 11
10 3
11 8
12 6
13 13
14 9
15 15
16 1
17 8
18 13
19 16
20 57

About Mengyuan Li

Mengyuan Li is a scholar working on Immunology, Cancer Research and Biological Psychiatry, having authored 219 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (18 papers), Ferroptosis and cancer prognosis (15 papers) and Inflammasome and immune disorders (13 papers). The work is most often cited by research in Infectious Diseases (1.2k citations), Cancer Research (799 citations) and Immunology (953 citations). Mengyuan Li has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Xiaosheng Wang, Lin Li, Yue Zhang, Zehang Jiang, Zhixian Liu, Zeinab Abdelrahman, Chunxiao Li, Junjie Wang, Yuhan Yang and Ping Jiang. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026